This clinical trial evaluated the effects of isoquercetin, a dietary supplement, on thrombo-inflammatory biomarkers in adults with stable sickle cell disease (SCD). The study aimed to determine if isoquercetin could reduce inflammation and blood clotting, potentially improving patient outcomes.